[go: up one dir, main page]

MX2014010589A - Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. - Google Patents

Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.

Info

Publication number
MX2014010589A
MX2014010589A MX2014010589A MX2014010589A MX2014010589A MX 2014010589 A MX2014010589 A MX 2014010589A MX 2014010589 A MX2014010589 A MX 2014010589A MX 2014010589 A MX2014010589 A MX 2014010589A MX 2014010589 A MX2014010589 A MX 2014010589A
Authority
MX
Mexico
Prior art keywords
pyrimidine
compositions
methods
based compounds
pyrazolo
Prior art date
Application number
MX2014010589A
Other languages
English (en)
Other versions
MX345830B (es
Inventor
Kenneth Gordon Carson
Giovanni Cianchetta
Yingzhi Bi
Michael Alan Green
Godwin Kumi
Alan Main
Yulian Zhang
Glenn Gregory Zipp
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of MX2014010589A publication Critical patent/MX2014010589A/es
Publication of MX345830B publication Critical patent/MX345830B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos a base de pirazol[1,5-a]pirimidina de la fórmula: (ver Fórmula) en donde R1, R2 y R3 se definen en la presente. También se describen las composiciones que comprenden los compuestos y métodos para su uso para tratar, manejar y/o prevenir enfermedades y trastornos mediados por la actividad de cinasa 1 asociada al adaptador.
MX2014010589A 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. MX345830B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (2)

Publication Number Publication Date
MX2014010589A true MX2014010589A (es) 2014-09-18
MX345830B MX345830B (es) 2017-02-17

Family

ID=47892052

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010589A MX345830B (es) 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
MX2017002117A MX381849B (es) 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017002117A MX381849B (es) 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.

Country Status (25)

Country Link
US (3) US8946415B2 (es)
EP (1) EP2834243B1 (es)
JP (1) JP6418950B2 (es)
KR (1) KR101965025B1 (es)
CN (1) CN104302649B (es)
AR (1) AR090292A1 (es)
AU (1) AU2013230128B2 (es)
BR (1) BR112014022000A8 (es)
CA (1) CA2866143C (es)
DK (1) DK2834243T3 (es)
ES (1) ES2676224T3 (es)
HU (1) HUE038786T2 (es)
IL (1) IL234486A (es)
IN (1) IN2014DN07384A (es)
MX (2) MX345830B (es)
NZ (1) NZ630721A (es)
PL (1) PL2834243T3 (es)
PT (1) PT2834243T (es)
RU (1) RU2014140735A (es)
SG (1) SG11201405561RA (es)
TR (1) TR201808280T4 (es)
TW (1) TW201341386A (es)
UY (1) UY34668A (es)
WO (1) WO2013134228A1 (es)
ZA (1) ZA201406149B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
CN104470523B (zh) 2012-03-09 2017-07-11 莱西肯医药有限公司 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN105121445A (zh) 2013-02-22 2015-12-02 百时美施贵宝公司 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
LT3572416T (lt) 2014-01-24 2022-12-27 Turning Point Therapeutics, Inc. Diarilo makrociklai, kaip baltymų kinazių moduliatoriai
WO2015116492A1 (en) * 2014-01-31 2015-08-06 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法
WO2016053794A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
CA2971024C (en) * 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
EP3292124B1 (en) 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
EP4397665A3 (en) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
US20180325901A1 (en) 2015-07-21 2018-11-15 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
UA122423C2 (uk) * 2015-11-02 2020-11-10 Янссен Фармацевтика Нв [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
AU2017353310B2 (en) * 2016-11-02 2021-08-12 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as PDE2 inhibitors
CA3038913A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
ES2855032T3 (es) 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
MY201925A (en) 2017-07-28 2024-03-23 Turning Point Therapeutics Inc Macrocyclic compounds and uses thereof
PT3658557T (pt) 2017-07-28 2024-09-11 Nimbus Lakshmi Inc Inibidores de tyk2 e usos dos mesmos
JP7321183B2 (ja) * 2017-12-15 2023-08-04 ピラミッド バイオサイエンシズ インコーポレイテッド がんを治療するためのｔｒｋキナーゼ阻害物質としての、５－（２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－３－（１ｈ－ピラゾール－１－イル）ピラゾロ［１，５－ａ］ピリミジン誘導体及び関連する化合物
PL3728271T3 (pl) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
CN111362949B (zh) * 2017-12-22 2021-12-21 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
CN109575025B (zh) 2018-01-23 2020-09-11 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
US20220041588A1 (en) * 2018-09-27 2022-02-10 Fochon Pharmaceuticals, Ltd. Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
AU2019360941B2 (en) * 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EP4138829A1 (en) 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections
JP2023522689A (ja) * 2020-04-21 2023-05-31 レクシコン ファーマシューティカルズ インコーポレイテッド ＣｏＶ－２２９Ｅ又はＣｏＶ－ＯＣ４３コロナウイルス感染症の治療において使用される４－（３－（ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－５－イル）ピペラジン
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
TW202525819A (zh) * 2023-09-08 2025-07-01 加拿大商薩泰洛斯生物科學公司 Ａｐ２相關激酶１抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CN102056927B (zh) * 2008-05-13 2014-06-25 Irm责任有限公司 作为激酶抑制剂的稠合含氮杂环及其组合物
KR102037619B1 (ko) * 2008-10-22 2019-10-28 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TW201113286A (en) 2009-09-03 2011-04-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
EP2523552B1 (en) 2010-01-14 2015-05-13 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
ES2834093T3 (es) * 2011-07-21 2021-06-16 Sumitomo Dainippon Pharma Oncology Inc Inhibidores de proteína quinasa heterocíclicos
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
CN104470523B (zh) 2012-03-09 2017-07-11 莱西肯医药有限公司 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法
HK1199814A1 (en) * 2012-03-09 2015-07-24 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
DK2834243T3 (en) 2018-07-23
US8946415B2 (en) 2015-02-03
KR101965025B1 (ko) 2019-04-02
NZ630721A (en) 2016-12-23
PT2834243T (pt) 2018-08-01
BR112014022000A2 (pt) 2017-06-20
KR20140138864A (ko) 2014-12-04
US9403832B2 (en) 2016-08-02
IN2014DN07384A (es) 2015-04-24
JP2015509535A (ja) 2015-03-30
ZA201406149B (en) 2016-06-29
PL2834243T3 (pl) 2018-09-28
TW201341386A (zh) 2013-10-16
IL234486A (en) 2016-10-31
CN104302649A (zh) 2015-01-21
CN104302649B (zh) 2017-06-23
AU2013230128B2 (en) 2017-08-17
CA2866143C (en) 2020-08-04
HUE038786T2 (hu) 2018-11-28
BR112014022000A8 (pt) 2021-06-15
EP2834243B1 (en) 2018-04-25
HK1201257A1 (en) 2015-08-28
RU2014140735A (ru) 2016-04-27
US20170129896A1 (en) 2017-05-11
SG11201405561RA (en) 2014-10-30
MX381849B (es) 2025-03-13
AR090292A1 (es) 2014-11-05
CA2866143A1 (en) 2013-09-12
WO2013134228A1 (en) 2013-09-12
UY34668A (es) 2013-10-31
US20150183792A1 (en) 2015-07-02
JP6418950B2 (ja) 2018-11-07
US20130253194A1 (en) 2013-09-26
MX345830B (es) 2017-02-17
TR201808280T4 (tr) 2018-07-23
ES2676224T3 (es) 2018-07-17
AU2013230128A1 (en) 2014-09-25
EP2834243A1 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
MX2014010589A (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
ECSP14013215A (es) Compuestos novedosos
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
GT201400196A (es) Compuestos de heterociclilo
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
CR20130371A (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY33078A (es) Derivados de imidazoquinolina
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
MX2018003186A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer.
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX2019005154A (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
ECSP16074478A (es) Compuestos novedosos
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
GT201400007A (es) Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.

Legal Events

Date Code Title Description
FG Grant or registration